Toshio Machida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toshio Machida has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Takaki Hiwasa
Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
7 shared publications - Yasuo Iwadate
Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
6 shared publications - Minoru Takemoto
Department of Medicine, Division of Diabetes, Metabolism and Endocrinology International University of Health and Welfare Narita Japan
5 shared publications Satoshi Ishige
Department of Neurosurgery, Eastern Chiba Medical Center, Togane, Chiba, Japan
5 shared publications- Eiichiro Nishi
Department of Pharmacology, Shiga University of Medical Science, Otsu, Japan
4 shared publications - Koutaro Yokote
Chiba University Chiba Japan
4 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (3)
Endovascular Therapy for Acute Ischemic Stroke Beyond 24 Hours After Onset: A Nationwide Registry-Based Analysis
BACKGROUND: This study aimed to evaluate the real-world status of endovascular therapy for acute ischemic stroke >24 hours after onset. METHODS: From the data set of Japan Stroke Data Bank, a nationwide, multicenter prospective registry of stroke within 7 days of onset, patients with acute ischemic stroke who underwent endovascular therapy from 2016 through 2021 were included. Patients were categorized into 3 groups according to time from onset to hospital arrival: early (24 hours). The primary outcome was a favorable functional status defined as a modified Rankin Scale (mRS) score of 0 to 2 at discharge for patients with a prestroke mRS score of 0 to 2, and return to prestroke mRS score at discharge for patients with a prestroke mRS score of 3 to 5. RESULTS: A total of 5862 patients were included (median age, 78 years; 42.7% women; median National Institutes of Health Stroke Scale score, 17; 83.8% with prestroke mRS score, 0–2), with 3988 in the early group, 1548 in the late group, and 326 in the very late group. The very late group was younger, had lower National Institutes of Health Stroke Scale scores, and a higher proportion of large artery atherosclerosis. The favorable functional status was achieved in 41.4%, 35.3%, and 45.7% of the early, late, and very late groups, respectively. In multivariable logistic analyses, both the late (adjusted odds ratio, 0.60 [95% CI, 0.52–0.69]) and very late (adjusted odds ratio, 0.72 [95% CI, 0.62–0.83]) groups showed lower odds of achieving a favorable functional status compared with the early group. When stratified by National Institutes of Health Stroke Scale score, achievement of the favorable functional status was less frequent in the late and very late groups, in that order, compared with the early group, particularly when the National Institutes of Health Stroke Scale score exceeded ≈10. CONCLUSIONS: In this nationwide registry, patients undergoing endovascular therapy >24 hours showed distinct clinical profiles, with crude outcomes comparable to patients treated in earlier time windows. These findings provide important context for the design and validation of randomized trials.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (3)
Open AccessEndovascular Therapy for Acute Ischemic Stroke Beyond 24 Hours After Onset: A Nationwide Registry-Based Analysis
BACKGROUND: This study aimed to evaluate the real-world status of endovascular therapy for acute ischemic stroke >24 hours after onset. METHODS: From the data set of Japan Stroke Data Bank, a nationwide, multicenter prospective registry of stroke within 7 days of onset, patients with acute ischemic stroke who underwent endovascular therapy from 2016 through 2021 were included. Patients were categorized into 3 groups according to time from onset to hospital arrival: early (24 hours). The primary outcome was a favorable functional status defined as a modified Rankin Scale (mRS) score of 0 to 2 at discharge for patients with a prestroke mRS score of 0 to 2, and return to prestroke mRS score at discharge for patients with a prestroke mRS score of 3 to 5. RESULTS: A total of 5862 patients were included (median age, 78 years; 42.7% women; median National Institutes of Health Stroke Scale score, 17; 83.8% with prestroke mRS score, 0–2), with 3988 in the early group, 1548 in the late group, and 326 in the very late group. The very late group was younger, had lower National Institutes of Health Stroke Scale scores, and a higher proportion of large artery atherosclerosis. The favorable functional status was achieved in 41.4%, 35.3%, and 45.7% of the early, late, and very late groups, respectively. In multivariable logistic analyses, both the late (adjusted odds ratio, 0.60 [95% CI, 0.52–0.69]) and very late (adjusted odds ratio, 0.72 [95% CI, 0.62–0.83]) groups showed lower odds of achieving a favorable functional status compared with the early group. When stratified by National Institutes of Health Stroke Scale score, achievement of the favorable functional status was less frequent in the late and very late groups, in that order, compared with the early group, particularly when the National Institutes of Health Stroke Scale score exceeded ≈10. CONCLUSIONS: In this nationwide registry, patients undergoing endovascular therapy >24 hours showed distinct clinical profiles, with crude outcomes comparable to patients treated in earlier time windows. These findings provide important context for the design and validation of randomized trials.
- Open Access
- 29 May 2025
- Published by Open Exploration Publishing in Exploration of Cardiology
- Vol. 3, 101258
Autoantibody against UBE2E3 is a common biomarker for atherosclerotic diseases and digestive tract cancer
Aim: Atherosclerosis and diabetes mellitus (DM) often lead to severe conditions, such as acute ischemic stroke (AIS), cardiovascular disease (CVD), and chronic kidney disease (CKD). Some cancers are also associated with atherosclerosis. Therefore, identifying novel autoantibody biomarkers associated with atherosclerosis-related conditions is crucial for improving early diagnosis and risk assessment. Methods: We used an array of 9,480 proteins to detect IgG antibodies in the serum of patients with atherosclerosis. Following this screening, we quantified the antibody levels using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) with recombinant antigen proteins. Results: Ubiquitin conjugating enzyme E2 E3 (UBE2E3) was identified as a candidate antigen recognized by IgG antibodies in the sera of individuals diagnosed with atherosclerosis. Compared with healthy donors, significantly higher serum antibody levels against UBE2E3 were found in patients with AIS, DM, CVD, CKD, esophageal cancer (EC), and gastric cancer (GC), but not in those with colorectal cancer (CRC). Receiver operating characteristic (ROC) analysis revealed that the higher areas under the ROC curves for anti-UBE2E3 antibodies were observed in DM- or nephrosclerosis-associated CKD than in the others. Spearman’s correlation analysis revealed that serum anti-UBE2E3 antibody (s-UBE2E3-Ab) levels were associated with the plaque score, maximum intima-media thickness, and cardio-ankle vascular index, which are typical indices of atherosclerosis and stenosis. In the survival analysis of GC and CRC, patients who were s-UBE2E3-Ab-positive had significantly poorer prognoses than patients who were s-UBE2E3-Ab-negative. The difference became more prominent when s-UBE2E3-Abs were combined with anti-differential screening-selected gene aberrant in neuroblastoma antibody (DAN-Ab) or sclerostin domain-containing protein 1 (SOSTDC1), which are bone morphogenetic protein (BMP) antagonists. Conclusions: The s-UBE2E3-Ab marker is highly associated with atherosclerosis-related diseases, such as AIS, CVD, DM, CKD, and digestive tract cancers, suggesting the involvement of BMP signals.
- 29 May 2025
- Published by Open Exploration Publishing in Exploration of Cardiology
- Vol. 3, 101258
Open AccessAutoantibody against UBE2E3 is a common biomarker for atherosclerotic diseases and digestive tract cancer
Aim: Atherosclerosis and diabetes mellitus (DM) often lead to severe conditions, such as acute ischemic stroke (AIS), cardiovascular disease (CVD), and chronic kidney disease (CKD). Some cancers are also associated with atherosclerosis. Therefore, identifying novel autoantibody biomarkers associated with atherosclerosis-related conditions is crucial for improving early diagnosis and risk assessment. Methods: We used an array of 9,480 proteins to detect IgG antibodies in the serum of patients with atherosclerosis. Following this screening, we quantified the antibody levels using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) with recombinant antigen proteins. Results: Ubiquitin conjugating enzyme E2 E3 (UBE2E3) was identified as a candidate antigen recognized by IgG antibodies in the sera of individuals diagnosed with atherosclerosis. Compared with healthy donors, significantly higher serum antibody levels against UBE2E3 were found in patients with AIS, DM, CVD, CKD, esophageal cancer (EC), and gastric cancer (GC), but not in those with colorectal cancer (CRC). Receiver operating characteristic (ROC) analysis revealed that the higher areas under the ROC curves for anti-UBE2E3 antibodies were observed in DM- or nephrosclerosis-associated CKD than in the others. Spearman’s correlation analysis revealed that serum anti-UBE2E3 antibody (s-UBE2E3-Ab) levels were associated with the plaque score, maximum intima-media thickness, and cardio-ankle vascular index, which are typical indices of atherosclerosis and stenosis. In the survival analysis of GC and CRC, patients who were s-UBE2E3-Ab-positive had significantly poorer prognoses than patients who were s-UBE2E3-Ab-negative. The difference became more prominent when s-UBE2E3-Abs were combined with anti-differential screening-selected gene aberrant in neuroblastoma antibody (DAN-Ab) or sclerostin domain-containing protein 1 (SOSTDC1), which are bone morphogenetic protein (BMP) antagonists. Conclusions: The s-UBE2E3-Ab marker is highly associated with atherosclerosis-related diseases, such as AIS, CVD, DM, CKD, and digestive tract cancers, suggesting the involvement of BMP signals.
- Open Access
- 30 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4935
JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases
Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima–media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.
- 30 April 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4935
Open AccessJMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases
Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima–media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.
- Open Access
- 17 January 2024
- Published by MDPI AG in Preprints.org
JMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases
Atherosclerosis is associated with vascular diseases, diabetes, and cancers. The Jumonji C-domain-containing 6 (JMJD6) gene plays an important role in diverse biological processes. In addition, autoantibodies are reportedly useful in the early diagnosis and treatment of many diseases. Here, JMJD6 was identified by serological identification of antigens by recombinant cDNA expression cloning as an antigen recognized by serum IgG from patients with unstable angina pectoris. Then, we performed amplified luminescent proximity homogeneous assay-linked immunosorbent assay using purified recombinant antigens and found elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with atherosclerosis-related diseases including ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers including esophageal cancer (EC), gastric cancer, lung cancer, and mammary cancer, compared with those in healthy donors. The s-JMJD6-Ab levels were closely associated with hypertension, habitual smoking, and the intima-media thickness, an atherosclerosis index. The better postoperative survival status was shown in patients with EC from the JMJD6-Ab-positive group than the negative group, especially from JMJD6-Ab-positive/PD-L1-negative group and JMJD6-Ab-positive/p53-Ab-negative group than JMJD6-Ab-negative/PD-L1-positive group and JMJD6-Ab-negative/p53-Ab-positive group, respectively. Hence, JMJD6 autoantibodies may reflect atherosclerosis severity, thereby a potential biomarker for atherosclerosis-related diseases including ischemic stroke, AMI, DM, and cancers and for predicting EC prognosis.
- 17 January 2024
- Published by MDPI AG in Preprints.org
Open AccessJMJD6 Autoantibodies as a Potential Biomarker for Atherosclerosis-Related Diseases
Atherosclerosis is associated with vascular diseases, diabetes, and cancers. The Jumonji C-domain-containing 6 (JMJD6) gene plays an important role in diverse biological processes. In addition, autoantibodies are reportedly useful in the early diagnosis and treatment of many diseases. Here, JMJD6 was identified by serological identification of antigens by recombinant cDNA expression cloning as an antigen recognized by serum IgG from patients with unstable angina pectoris. Then, we performed amplified luminescent proximity homogeneous assay-linked immunosorbent assay using purified recombinant antigens and found elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with atherosclerosis-related diseases including ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers including esophageal cancer (EC), gastric cancer, lung cancer, and mammary cancer, compared with those in healthy donors. The s-JMJD6-Ab levels were closely associated with hypertension, habitual smoking, and the intima-media thickness, an atherosclerosis index. The better postoperative survival status was shown in patients with EC from the JMJD6-Ab-positive group than the negative group, especially from JMJD6-Ab-positive/PD-L1-negative group and JMJD6-Ab-positive/p53-Ab-negative group than JMJD6-Ab-negative/PD-L1-positive group and JMJD6-Ab-negative/p53-Ab-positive group, respectively. Hence, JMJD6 autoantibodies may reflect atherosclerosis severity, thereby a potential biomarker for atherosclerosis-related diseases including ischemic stroke, AMI, DM, and cancers and for predicting EC prognosis.
- Open Access
- 1 January 2022
- Published by The Japanese Society for Neuroendovascular Therapy in Journal of Neuroendovascular Therapy
- Vol. 16 (11) , 542-546
Validity about Diameter of Guiding Catheter for Posterior Circulation Derived by MRA Study
Objective: The development of large-bore aspiration catheters (ACs) has advanced the treatment of mechanical thrombectomy (MT) and their use requires larger guiding catheters (GCs). However, due to the small vessel diameter of the vertebral artery (VA), it can be difficult to cannulate large-bore GC to the VA. This study aims to determine the percentage of VAs that are amenable to GC placement based on the use of a large-bore AC and to clarify the diameters of VAs in the general population using neck MRA. Methods: Left and right VA diameters were measured in 1394 consecutive adult patients who underwent neck MRA at our hospital between April 2020 and June 2021. Sex and left/right differences in the VA diameters, as well as the conformity ratios of GCs (6, 7, and 8 French) to right and left VAs, were examined. Results: The patients ranged in age from 18 to 98 years (mean 70.8 ± 13.5 years), with 770 (55.2%) males. The left and right VA mean diameters were 2.82 ± 0.75 mm (range 0–5.1 mm) and 2.65 ± 0.75 mm (range 0–5.3 mm), respectively. The conformity ratios of 6, 7, and 8 French GC to left and right VAs were 85.3% and 79.9%, 74.9% and 68.4%, and 60.9% and 53.7%, respectively. Conclusion: When performing MT for the posterior circulation system, a large-bore AC of 0.060 inches or larger is usually required, and GC placement of 7-French or larger is necessary. The results of this study showed that 7-French GC placement is achievable in approximately 70% of these cases.
- 1 January 2022
- Published by The Japanese Society for Neuroendovascular Therapy in Journal of Neuroendovascular Therapy
- Vol. 16 (11) , 542-546
Open AccessValidity about Diameter of Guiding Catheter for Posterior Circulation Derived by MRA Study
Objective: The development of large-bore aspiration catheters (ACs) has advanced the treatment of mechanical thrombectomy (MT) and their use requires larger guiding catheters (GCs). However, due to the small vessel diameter of the vertebral artery (VA), it can be difficult to cannulate large-bore GC to the VA. This study aims to determine the percentage of VAs that are amenable to GC placement based on the use of a large-bore AC and to clarify the diameters of VAs in the general population using neck MRA. Methods: Left and right VA diameters were measured in 1394 consecutive adult patients who underwent neck MRA at our hospital between April 2020 and June 2021. Sex and left/right differences in the VA diameters, as well as the conformity ratios of GCs (6, 7, and 8 French) to right and left VAs, were examined. Results: The patients ranged in age from 18 to 98 years (mean 70.8 ± 13.5 years), with 770 (55.2%) males. The left and right VA mean diameters were 2.82 ± 0.75 mm (range 0–5.1 mm) and 2.65 ± 0.75 mm (range 0–5.3 mm), respectively. The conformity ratios of 6, 7, and 8 French GC to left and right VAs were 85.3% and 79.9%, 74.9% and 68.4%, and 60.9% and 53.7%, respectively. Conclusion: When performing MT for the posterior circulation system, a large-bore AC of 0.060 inches or larger is usually required, and GC placement of 7-French or larger is necessary. The results of this study showed that 7-French GC placement is achievable in approximately 70% of these cases.
- Open Access
- 1 September 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 25
Intracerebral hemorrhage due to a rete middle cerebral artery-related rupture of a distal lenticulostriate artery aneurysm: Two case reports
- 1 September 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 25
Open AccessIntracerebral hemorrhage due to a rete middle cerebral artery-related rupture of a distal lenticulostriate artery aneurysm: Two case reports
- Open Access
- 16 September 2020
- Published by Wiley in Cancer Science
- Vol. 111 (12) , 4453-4464
Serum anti‐LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases
Some cancers are related to atherosclerotic diseases; therefore, these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening of sera was performed from patients with esophageal squamous cell carcinoma (ESCC) or acute ischemic stroke (AIS) for serological identification of antigens using recombinant cDNA expression cloning (SEREX). The amplified luminescent proximity homogeneous assay‐linked immunosorbent assay (AlphaLISA) method, which incorporates glutathione donor beads and anti‐human IgG acceptor beads, was used to evaluate serum antibody levels. SEREX screening identified low‐density lipoprotein receptor–related protein–associated protein 1 (LRPAP1) as a target antigen of serum IgG antibodies in the sera of patients with ESCC or AIS. Antigens, including recombinant glutathione S‐transferase–fused LRPAP1 protein, were prepared to examine serum antibody levels. AlphaLISA revealed significantly higher antibody levels against the LRPAP1 protein in patients with solid cancers such as ESCC and colorectal carcinoma and some atherosclerosis‐related diseases such as AIS and diabetes mellitus compared with healthy donors. Correlation analysis revealed that the elevated serum antibody levels against LRPAP1 were associated with smoking, a well‐known risk factor for both cancer and atherosclerosis. Serum LRPAP1 antibody is therefore a common marker for the early diagnosis of some cancers and atherosclerotic diseases and may reflect diseases caused by habitual smoking.
- 16 September 2020
- Published by Wiley in Cancer Science
- Vol. 111 (12) , 4453-4464
Open AccessSerum anti‐LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases
Some cancers are related to atherosclerotic diseases; therefore, these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening of sera was performed from patients with esophageal squamous cell carcinoma (ESCC) or acute ischemic stroke (AIS) for serological identification of antigens using recombinant cDNA expression cloning (SEREX). The amplified luminescent proximity homogeneous assay‐linked immunosorbent assay (AlphaLISA) method, which incorporates glutathione donor beads and anti‐human IgG acceptor beads, was used to evaluate serum antibody levels. SEREX screening identified low‐density lipoprotein receptor–related protein–associated protein 1 (LRPAP1) as a target antigen of serum IgG antibodies in the sera of patients with ESCC or AIS. Antigens, including recombinant glutathione S‐transferase–fused LRPAP1 protein, were prepared to examine serum antibody levels. AlphaLISA revealed significantly higher antibody levels against the LRPAP1 protein in patients with solid cancers such as ESCC and colorectal carcinoma and some atherosclerosis‐related diseases such as AIS and diabetes mellitus compared with healthy donors. Correlation analysis revealed that the elevated serum antibody levels against LRPAP1 were associated with smoking, a well‐known risk factor for both cancer and atherosclerosis. Serum LRPAP1 antibody is therefore a common marker for the early diagnosis of some cancers and atherosclerotic diseases and may reflect diseases caused by habitual smoking.
- 1 January 2018
- Published by Japanese Society on Surgery for Cerebral Stroke in Surgery for Cerebral Stroke
- Vol. 46 (3) , 184-188
Delayed Anterior Choroidal Artery Territory Infarction after Carotid Ligation Surgery with an Extracranial to Intracranial High-flow Bypass for a Large Cavernous Carotid Aneurysm: A Case Report
A 65-year-old female presented with right oculomotor nerve palsy due to a large internal carotid artery (ICA) cavernous aneurysm. She underwent ligation of the right ICA with an external carotid artery to middle cerebral artery high-flow bypass (HFB).Although her postoperative course was uneventful, she developed a cerebral infarction at the right internal capsule 5 months after surgery.Cerebral angiography revealed a filling defect at the origin of the anterior choroidal artery. We suspected that the blood current from HFB and the posterior communicating artery formed a “currentrip” at the C1 segment of the right ICA. Soon after introduction of antithrombotic therapy, her symptoms completely resolved.Angiography 3 months after the stroke revealed no filling defect at that site.This is the first report demonstrating the occurrence of ischemic stroke in the chronic phase of carotid ligation surgery with HFB. Hence, careful observation is required for these patients, even after discharge.
- 1 January 2018
- Published by Japanese Society on Surgery for Cerebral Stroke in Surgery for Cerebral Stroke
- Vol. 46 (3) , 184-188
Delayed Anterior Choroidal Artery Territory Infarction after Carotid Ligation Surgery with an Extracranial to Intracranial High-flow Bypass for a Large Cavernous Carotid Aneurysm: A Case Report
A 65-year-old female presented with right oculomotor nerve palsy due to a large internal carotid artery (ICA) cavernous aneurysm. She underwent ligation of the right ICA with an external carotid artery to middle cerebral artery high-flow bypass (HFB).Although her postoperative course was uneventful, she developed a cerebral infarction at the right internal capsule 5 months after surgery.Cerebral angiography revealed a filling defect at the origin of the anterior choroidal artery. We suspected that the blood current from HFB and the posterior communicating artery formed a “currentrip” at the C1 segment of the right ICA. Soon after introduction of antithrombotic therapy, her symptoms completely resolved.Angiography 3 months after the stroke revealed no filling defect at that site.This is the first report demonstrating the occurrence of ischemic stroke in the chronic phase of carotid ligation surgery with HFB. Hence, careful observation is required for these patients, even after discharge.
- 1 January 2018
- Published by Elsevier in World Neurosurgery
- Vol. 109, 204-208
Postoperative Cerebral Ischemia Due to Hypotension in Moyamoya Patient with Autonomic Dysfunction
- 1 January 2018
- Published by Elsevier in World Neurosurgery
- Vol. 109, 204-208
Postoperative Cerebral Ischemia Due to Hypotension in Moyamoya Patient with Autonomic Dysfunction
- Open Access
- 24 December 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (10) , 8836-8848
Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack
Background: Disease specific autoantibodies have been detected in the sera of patients with atherosclerosis-related diseases, such as cerebral infarction, cardiovascular disease. In the present study, we aimed to identify novel autoantibodies responsible for transient ischemic attack (TIA), a prodromal condition for cerebral infarction.
- 24 December 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (10) , 8836-8848
Open AccessElevation of autoantibody level against PDCD11 in patients with transient ischemic attack
Background: Disease specific autoantibodies have been detected in the sera of patients with atherosclerosis-related diseases, such as cerebral infarction, cardiovascular disease. In the present study, we aimed to identify novel autoantibodies responsible for transient ischemic attack (TIA), a prodromal condition for cerebral infarction.